168 related articles for article (PubMed ID: 36246597)
21. Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis.
Lin Y; Li T; Li Z; Shen C; Wu Z; Zhang Z; Li Z; Yang S; Wang Z; Li P; Fu C; Guo J; Hu H
Front Genet; 2023; 14():1097179. PubMed ID: 37091788
[No Abstract] [Full Text] [Related]
22. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
23. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
24. The Immune Cell Infiltration Patterns and Characterization Score in Bladder Cancer to Identify Prognosis.
Zhang Y; Wang Y; Wang J; Zhang K
Front Genet; 2022; 13():852708. PubMed ID: 35801082
[No Abstract] [Full Text] [Related]
25. A novel prognostic and therapeutic target biomarker based on necroptosis-related gene signature and immune microenvironment infiltration in gastric cancer.
Xin D; Man Y; Yang Y; Wang F
Front Genet; 2022; 13():953997. PubMed ID: 36092932
[No Abstract] [Full Text] [Related]
26. A novel signature constructed by ferroptosis-associated genes (FAGs) for the prediction of prognosis in bladder urothelial carcinoma (BLCA) and associated with immune infiltration.
Luan JC; Zeng TY; Zhang QJ; Xia DR; Cong R; Yao LY; Song LB; Zhou X; Zhou X; Chen X; Xia JD; Song NH
Cancer Cell Int; 2021 Aug; 21(1):414. PubMed ID: 34362387
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment.
Chen J; Lv B; Zhan Y; Zhu K; Zhang R; Chen B; Jin Y; Li Y; Zheng J; Lin C
Front Oncol; 2022; 12():724261. PubMed ID: 35237505
[TBL] [Abstract][Full Text] [Related]
28. Identification and Assessment of Necroptosis-Related Genes in Clinical Prognosis and Immune Cells in Diffuse Large B-Cell Lymphoma.
Zhang Q; Zhu Z; Guan J; Zheng C
Front Oncol; 2022; 12():904614. PubMed ID: 35814424
[TBL] [Abstract][Full Text] [Related]
29. A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer.
Wang Z; Huang Z; Cao X; Zhang F; Cai J; Tang P; Yang C; Li S; Yu D; Yan Y; Shen B
BMC Urol; 2023 Jan; 23(1):10. PubMed ID: 36709279
[TBL] [Abstract][Full Text] [Related]
30. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
31. A Necroptosis-Related lncRNA to Develop a Signature to Predict the Outcome, Immune Landscape, and Chemotherapeutic Responses in Bladder Urothelial Carcinoma.
Hou J; Lu Z; Dong R; Wu G; Nie H; Yang G; Tang C; Qu G; Xu Y
Front Oncol; 2022; 12():928204. PubMed ID: 35814472
[TBL] [Abstract][Full Text] [Related]
32. Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis.
Cai D; Zhou Z; Wei G; Wu P; Kong G
Front Genet; 2022; 13():952369. PubMed ID: 36118856
[No Abstract] [Full Text] [Related]
33.
Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
[TBL] [Abstract][Full Text] [Related]
34. Integrated Analysis of Necroptosis-Related Genes for Prognosis, Immune Microenvironment Infiltration, and Drug Sensitivity in Colon Cancer.
He R; Zhang M; He L; Huang J; Man C; Wang X; Lang Y; Fan Y
Front Med (Lausanne); 2022; 9():845271. PubMed ID: 35479956
[TBL] [Abstract][Full Text] [Related]
35. Immunological significance of alternative splicing prognostic signatures for bladder cancer.
Li X; Yang L; Huang W; Jia B; Lai Y
Heliyon; 2022 Feb; 8(2):e08994. PubMed ID: 35243106
[TBL] [Abstract][Full Text] [Related]
36. Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature.
Li T; Jiang N; Bai Y; Liu T; Zhao Z; Xu X; Zhang Y; Wei F; Sun R; Liu S; Li J; Guo H; Yang R
Heliyon; 2023 Mar; 9(3):e13661. PubMed ID: 36873527
[TBL] [Abstract][Full Text] [Related]
37. Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer.
Yao Z; Zhang H; Zhang X; Zhang Z; Jie J; Xie K; Li F; Tan W
Front Genet; 2022; 13():923768. PubMed ID: 36147509
[TBL] [Abstract][Full Text] [Related]
38. Identification and validation of necroptosis-related prognostic gene signature and tumor immune microenvironment infiltration characterization in esophageal carcinoma.
Sun K; Hong JJ; Chen DM; Luo ZX; Li JZ
BMC Gastroenterol; 2022 Jul; 22(1):344. PubMed ID: 35840882
[TBL] [Abstract][Full Text] [Related]
39. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
40. Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
Zhang L; Li L; Zhan Y; Wang J; Zhu Z; Zhang X
Front Oncol; 2020; 10():542140. PubMed ID: 33552945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
